Lyophilisation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Successful bead beating is dependent not only on design features of the shaking machine (which take into consideration shaking oscillations frequency, shaking throw or distance, shaking orientation and vial orientation), but also the selection of correct bead size (0.1–6 mm (0.004–0.2 in) diameter), bead composition (glass, ceramic, steel) and bead load in the vial. In most laboratories, bead beating is done in batch sizes of one to twenty-four sealed, plastic vials or centrifuge tubes. The sample and tiny beads are agitated at about 2000 oscillations per minute in specially designed reciprocating shakers driven by high power electric motors. Cell disruption is complete in 1–3 minutes of shaking. Significantly faster rates of cell disruption are achieved with a bead beater variation called SoniBeast. Differing from conventional machines, it agitates the beads using a vortex motion at 20,000 oscillations per minute. Larger bead beater machines that hold deep-well microtiter plates also shorten process times, as do Bead Dispensers designed to quickly load beads into multiple vials or microplates. Pre-loaded vials and microplates are also available. All high energy bead beating machines warm the sample about 10 degrees per minute. This is due to frictional collisions of the beads during homogenization. Cooling of the sample during or after bead beating may be necessary to prevent damage to heat-sensitive proteins such as enzymes.
=== Subjective effects === Subjective experiences of DMT indubitably includes profound time-dilatory, visual, auditory, tactile, and proprioceptive distortions and hallucinations, and other experiences that, by most firsthand accounts, defy verbal or visual description. Examples include perceiving hyperbolic geometry or seeing Escher-like impossible objects. Several scientific experimental studies have tried to measure subjective experiences of altered states of consciousness induced by drugs under highly controlled and safe conditions. Rick Strassman and his colleagues conducted a five-year-long DMT study at the University of New Mexico in the 1990s. The results provided insight about the quality of subjective psychedelic experiences. In this study participants received the DMT dose via intravenous injection and the findings suggested that different psychedelic experiences can occur, depending on the dose. Lower doses (0.01 and 0.05 mg/kg) produced some aesthetic and emotional responses, but not hallucinogenic experiences (e.g., 0.05 mg/kg had mild mood elevating and calming properties). In contrast, responses produced by higher doses (0.2 and 0.4 mg/kg) researchers labeled as "hallucinogenic" that elicited "intensely colored, rapidly moving display of visual images, formed, abstract or both". Comparing to other sensory modalities, the most affected was the visual.
Lauer of the Kitt Peak National Observatory; the Hubble constant was determined from supernovae, known as standard candles or the cosmic distance ladder; Fermilab thought the age of the universe was around 20 billion years, which would imply a low Hubble constant; helioseismology was a new method; astrophysicist Michael Rowan-Robinson of Imperial College; French Pierre Lamarque and the age of globular clusters; astrophysicist Simon White of the University of Cambridge, and how the Moon weighs 80 times less than the Earth; John Huchra; physicist Neil Turok of Princeton University and physicist Alan Guth of MIT, and the universe's density parameter Ω, calculated from the Friedmann equations; Mexican Carlos Frenk of Durham University; the higher the Hubble constant, a conventional explanation of the Big Bang was more difficult; Jim Peebles of Princeton University; physicist Frank Close and perception of time. Narrated by Charlotte Cornwell. Part of the programme led to The Time Machine (Alan Parsons album) in 1999 (Parsons also made the music for the episode). Directed by Storm Thorgerson, produced by Geoff Deehan, made by Union Pictures 16 October Hypnosis - The Big Sleep, with Nicholas Spanos of Canada, and John Gruzelier and Graham Wagstaffe of the University of Liverpool; the documentary has scenes of gruesome medical procedures; Australian John Gruzelier of Charing Cross and Westminster Medical School; the 1923 poem Stopping by Woods on a Snowy Evening by Robert Frost; Helen Crawford of Virginia State University, and chronic pain and evoked potential; Karl H.
Epitalon is a synthetic peptide, telomerase activator, and putative anti-aging compound, which was identified as the putative active component of a bovine pineal gland extract known as epithalamin. Most studies on epitalon and epithalamin have been conducted by the St. Petersburg Institute of Bioregulation and Gerontology, primarily overseen by Vladimir Khavinson, in Russia, though in recent years research using epitalon has started to be conducted elsewhere, focusing mainly on its ability to extend telomere length.
Sources: en.wikipedia.org
The first arc of the series, Trails in the Sky, consists of three games. They are set within the Liberl Kingdom and primarily follow Estelle Bright and her adopted brother Joshua, members of the Bracer's Guild, a civilian peacekeeping and monster-hunting organization. The first game, Trails in the Sky, was released in Japan in 2004 for Windows and for the PlayStation Portable (PSP) in 2006. The second game, Trails in the Sky SC, continues the plot of the first and was released in Japan for Windows in 2006 and the PSP the following year. The third game, Trails in the Sky the 3rd, follows Septian Church agent Kevin Graham, who is sent to an otherworldly dimension known as Phantasma alongside many characters from the previous two games. Sky the 3rd also features vignettes exploring character backstories as well as foreshadowing plot elements explored in later arcs. It was released in Japan in 2007 for Windows and the PSP in 2008. A 3D remake of the first game, Trails in the Sky 1st Chapter, released worldwide for Nintendo Switch, Nintendo Switch 2, PlayStation 5, and Windows in 2025. A remake of the sequel, Trails in the Sky 2nd Chapter, has been released for the same platforms in 2026. In 2010, Xseed Games acquired the rights to localize and publish the trilogy in English.
== Tissue distribution == The 5-HT3 receptor is expressed throughout the central and peripheral nervous systems and mediates a variety of physiological functions. On a cellular level, it has been shown that postsynaptic 5-HT3 receptors mediate fast excitatory synaptic transmission in rat neocortical interneurons, amygdala, and hippocampus, and in ferret visual cortex. 5-HT3 receptors are also present on presynaptic nerve terminals. There is some evidence for a role in modulation of neurotransmitter release, but evidence is inconclusive.
== Adverse effects == Cefodizime has been shown to be generally well tolerated in drug trials and its adverse effects are mainly gastrointestinal or dermatological. Gastrointestinal adverse effects were observed in 2.4% of patients during clinical trials and included: diarrhea, nausea, vomiting, and elevated transaminases. Allergic symptoms were observed in 1.1% of patients and include: exanthema, urticaria, and pruritus. Other adverse effects observed include local site reactions, pain at site of injection, and phlebitis.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.